Autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, diabetes and lupus, etc., affect approximately 50 million Americans. The immune responses of self-reactive T lymphocytes play critical roles in autoimmune diseases. Therefore, identification of novel molecules that regulate T cell immune functions are important for a better understanding of the mechanisms underlying the disease development and for seeking novel therapies. During the current finding period, we have discovered that the type III histone deacetylase Sirt1 as a critical suppressor to T cell immunity and macrophage activation by suppressing the transcription factors AP-1, indicating Sirt1 as a potential therapeutic target for autoimmune and inflammatory diseases. In fact, we further demonstrated that the Sirt1 activator resveratrol prevents/treats type 1 diabetes in mice. Our preliminary study of the current competitive renewal application demonstrates that the deacetylase Sirt1 and the acetyltransferase GCN5 oppositely regulate T cell activation. Genetic deletion of GCN5 gene inhibits T cell immune responses in mice, identifying GCN5 as a critical positive regulator for T cell immunity. Interestingly, treatment of mice with GCN5 specific inhibitor attenuated autoimmune disease development. Therefore, based on the above preliminary findings, we propose that the histone deacetylase Sirt1 is a negative regulator and the acetyltransferase GCN5 is a positive regulator for T cell immunity, and that the Sirt1 activator and GCN5 inhibitor have great therapeutic potentials in treatment of autoimmune diseases. This project is to address this hypothesis using the state-of-art approaches of both immunological and molecular studies. Results from this proposed study discover novel molecular mechanisms behind Sirt1 and GCN5 in T cell activation and autoimmunity, providing rationales for the uses of Sirt1 deacetylase activators and GCN5 acetyltransferase inhibitors in treating/preventing autoimmune diseases.
This study identifies the histone deacetylase Sirt1 as a negative regulator and the acetyltransferase GCN5 as a positive regulator for T cell immune response. Therefore, Sirt1 activators and GCN5 inhibitors have great therapeutic potentials in the treatment of autoimmune diseases.
|Melo-Cardenas, Johanna; Xu, Yuanming; Wei, Juncheng et al. (2018) USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. Blood 132:423-434|
|Wang, Wenhui; Li, Fei; Xu, Yuanming et al. (2018) JAK1-mediated Sirt1 phosphorylation functions as a negative feedback of the JAK1-STAT3 pathway. J Biol Chem 293:11067-11075|
|Yang, Yi; Kong, Sinyi; Zhang, Yana et al. (2018) The endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls a critical checkpoint in B cell development in mice. J Biol Chem 293:12934-12944|
|Wei, Juncheng; Chen, Lu; Li, Fei et al. (2018) HRD1-ERAD controls production of the hepatokine FGF21 through CREBH polyubiquitination. EMBO J 37:|
|Hou, Xia; Yang, Zhao; Zhang, Kezhong et al. (2017) SUMOylation represses the transcriptional activity of the Unfolded Protein Response transducer ATF6. Biochem Biophys Res Commun 494:446-451|
|Wang, Yajun; Yun, Chawon; Gao, Beixue et al. (2017) The Lysine Acetyltransferase GCN5 Is Required for iNKT Cell Development through EGR2 Acetylation. Cell Rep 20:600-612|
|Gao, Beixue; Kong, Qingfei; Zhang, Yana et al. (2017) The Histone Acetyltransferase Gcn5 Positively Regulates T Cell Activation. J Immunol 198:3927-3938|
|Kong, Sinyi; Yang, Yi; Xu, Yuanming et al. (2016) Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas. Proc Natl Acad Sci U S A 113:10394-9|
|Principe, Daniel R; DeCant, Brian; Mascariñas, Emman et al. (2016) TGF? Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 76:2525-39|
|Haque, Mohammad; Song, Jianyong; Fino, Kristin et al. (2016) Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity. Sci Rep 6:20588|
Showing the most recent 10 out of 40 publications